Circulating glucocorticoid bioactivity during peroral glucocorticoid treatment in children and adolescents with inflammatory bowel disease.

Goals: Our objective was to investigate the changes in circulating glucocorticoid bioactivity (GBA) at the onset of systemic glucocorticoid therapy in pediatric patients with inflammatory bowel disease. Study: Prednisolone (1 mg/kg/d) or budesonide (9 mg/d) was introduced as a single daily dose, and the patients (n = 22) were Subsequently followed up at 2 to 4 week intervals. The limit for a raised value of serum GBA was defined in pediatric patients (mean+2 SD; 118 nM cortisol equivalents; n = 142). Results: Two weeks of prednisolone brought about all increase ill serum GBA from 84 +/- 14 to 336 +/- 38 nM cortisol equivalents (mean +/- SE; P < 0.001). Young patients ( < 10 y) had similar GBA values to older patients. even though their prednisolone dose was higher (1.3 vs. 0.79 mg/kg; P<0.05). Patients treated with budesonide displayed a minor increase in GBA (151 20 vs. 267 21 nM cortisol equivalents after 4 wk of treatment; P < 0.05; it = 3) and when switched to prednisolone (n = 2), their GBA level increased 3-fold. GBA levels did not predict the development of glucocorticoid-related side effects. Conclusions: Prednisolone Closes used in the treatment of pediatric inflammatory bowel disease patients elicit a 4-fold increase in Serum GBA that is significantly higher than the increase induced by budesonide. The GBA measurement is all additional tool for assessing steroid therapy at an individual level during systemic glucocorticoid treatment.